180 Life Sciences Corp (ATNF)

Overview News Price History Discussions Forecast Stock Split

180 Life Sciences Corp stock is currently priced at $1.83, with a 24-hour trading volume of 90,637. It has seen a -4.19% decreased in the last 24 hours and a -45.86% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $1.79 pivot point. If it approaches the $2.11 resistance level, significant changes may occur.

180 Life Sciences Corp Stock (ATNF) Financials Data

180 Life Sciences Corp (ATNF) Net Income 2024

ATNF net income (TTM) was -$19.94 million for the quarter ending December 31, 2023, a +48.52% increase year-over-year.

180 Life Sciences Corp (ATNF) Cash Flow 2024

ATNF recorded a free cash flow (TTM) of -$10.92 million for the quarter ending December 31, 2023, a +9.94% increase year-over-year.

180 Life Sciences Corp (ATNF) Earnings per Share 2024

ATNF earnings per share (TTM) was -$64.27 for the quarter ending December 31, 2023, a +82.40% growth year-over-year.

180 Life Sciences Corp Stock (ATNF) Latest News

180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement

GlobeNewswire Inc.

180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan

GlobeNewswire Inc.

Why TechTarget Shares Are Trading Higher By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

US Stocks Higher; Inflation Rate Increases To 3.4% In December

Benzinga

Why Richardson Electronics Shares Are Trading Lower By 13%; Here Are 20 Stocks Moving Premarket

Benzinga

Why Resources Connection Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket

Benzinga

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.